Clinical Trials

Phase 2 Active not recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03269669 2026-03-18

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

73 enrolled

Lymphoma, Follicular

NCT03907475 2026-03-18

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Phase 3 Active not recruiting

115 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03914625 2026-03-18

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

6,720 enrolled

Phase 2/3 Active not recruiting

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03984448 2026-03-18

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

363 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04301076 2026-03-18

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Phase 1 Suspended

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04628767 2026-03-18

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2/3 Recruiting

249 enrolled

Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

NCT04799275 2026-03-18

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Phase 2/3 Suspended

422 enrolled

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT06058377 2026-03-18

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

3,680 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT06317662 2026-03-18

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

153 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT06422806 2026-03-18

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

365 enrolled

Phase 1 Not yet recruiting

Liposarcoma, Histiocytoma, Malignant Fibrous

NCT07444710 2026-03-18

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

16 enrolled

Phase 3 Active not recruiting

Ann Arbor Stage II Mantle Cell Lymphoma

NCT02306161 2026-03-17

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

312 enrolled 14 charts

Sarcoma, Ewing

NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

45 enrolled

Neoplasm Metastasis, Osteosarcoma

NCT00006721 2026-03-16

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Phase 3 Completed

571 enrolled 12 charts

Lymphoma, Lymphoma, Follicular

NCT07194044 2026-03-16

METTSEO

Phase 1 Recruiting

15 enrolled

Sarcoma, Ewing

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05453500 2026-03-13

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Burkitt Lymphoma

NCT06124157 2026-03-13

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

222 enrolled

Burkitt Lymphoma

NCT06717347 2026-03-13

MK-2140-010

1,046 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06738368 2026-03-13

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Phase 2 Active not recruiting

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04293393 2026-03-12

CARABELA

200 enrolled 27 charts

Breast

Breast Neoplasms

NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Phase 1 Recruiting

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07078604 2026-03-12

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Phase 2 Active not recruiting

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT00092222 2026-03-11

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

75 enrolled

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

NCT02213913 2026-03-11

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Phase 1/2 Completed

55 enrolled 17 charts